Please use this identifier to cite or link to this item:
Title: Anti-Mycobacterium abscessus activity of tuberculosis F-ATP synthase inhibitor GaMF1
Authors: Ragunathan, Priya
Dick, Thomas
Grüber, Gerhard
Keywords: Science::Chemistry::Biochemistry
Issue Date: 2022
Source: Ragunathan, P., Dick, T. & Grüber, G. (2022). Anti-Mycobacterium abscessus activity of tuberculosis F-ATP synthase inhibitor GaMF1. Antimicrobial Agents and Chemotherapy, 66(5), e00018-22-.
Project: NRF–CRP18–2017–01
Journal: Antimicrobial Agents and Chemotherapy 
Abstract: New drug targets and molecules with bactericidal activity are needed against the respiratory mycobacterial pathogen Mycobacterium abscessus (Mab). Employing a lead repurposing strategy, the anti-tuberculosis compound GaMF1 was tested against Mab. Whole cell- and ATP synthesis assays demonstrated that GaMF1 inhibits growth and kills Mab by targeting the F-ATP synthase. GaMF1’s anti-Mab activity increased in combination with clofazimine, rifabutin or amikacin The study expands the repertoire of anti-Mab compounds targeting oxidative phosphorylation.
ISSN: 0066-4804
DOI: 10.1128/aac.00018-22
Rights: © 2022 American Society for Microbiology. All Rights Reserved. This paper was published in Antimicrobial Agents and Chemotherapy and is made available with permission of American Society for Microbiology.
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:SBS Journal Articles

Files in This Item:
File Description SizeFormat 
AAC00018-22R1_Merged_PDF.pdf1.1 MBAdobe PDFView/Open

Page view(s)

Updated on Nov 25, 2022


Updated on Nov 25, 2022

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.